Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Corsair Gaming Inc (CRSR) vs Novavax Inc (NVAX) Price & Performance

Corsair Gaming IncTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Corsair Gaming Inc vs Novavax Inc — how do they compare? Corsair Gaming Inc trades at $13.58 (market cap $1.42B), while Novavax Inc trades at $12.97 (market cap $1.82B). The key difference: Novavax Inc is the larger of the two by market cap, and Novavax Inc is trading nearer its 52-week high, Corsair Gaming Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Corsair Gaming Inc for 25 Days and Novavax Inc for 59 Days on average.

CRSRNVAX
Market Cap
$1.42B$1.82B
Volume
1,160,9386,198,505
Sector
TechnologyHealth
52-Week High
$14.35$12.56
52-Week Low
$4.58$6.22
Typical Hold Time
25 Days59 Days
Enterprise Value
$1.41B$1.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Corsair Gaming Inc

Corsair Gaming (CRSR) trades at $13.505, down 0.63% on the day, with a bullish technical signal and recent earnings beats driving positive momentum. The stock shows improving fundamentals with a projected net income margin of 2.53% for 2026, though current valuation metrics like a P/E of 42.23 appear elevated. Recent product launches and strategic acquisitions highlight growth initiatives in the gaming and creator segments.

The outlook is cautiously optimistic, supported by analyst buy ratings and strong cash flow projections for 2026. Key risks include competitive pressures and reliance on consumer discretionary spending, but institutional interest and earnings outperformance provide a foundation for potential upside if execution continues.

Novavax Inc

Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.

Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CRSR
100% Buy0% Sell
Avg holding period · 25 Days
NVAX
55% Buy45% Sell
Avg holding period · 59 Days

Top news

Latest headlines on both assets

About Corsair Gaming Inc

Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment

Read more on CRSR →

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX →